Nitrofurantoin (Macrobid) Safety and Dosing in Pregnancy
Nitrofurantoin is safe to use during pregnancy except at term (last 4 weeks before delivery), and the recommended dose is 100 mg twice daily for 7 days for treatment of asymptomatic bacteriuria or UTI.
Safety Profile
Nitrofurantoin is classified as FDA Pregnancy Category B, meaning animal studies show no fetal harm, though adequate human studies are limited 1. The drug should be used during pregnancy "only if clearly needed" according to the FDA label, but substantial clinical evidence supports its safety profile:
First trimester exposure: Large population-based studies demonstrate no increased risk of major congenital malformations. A Norwegian cohort of 1,334 first-trimester exposures showed a malformation rate of 2.3% compared to 2.8% in disease controls (OR 0.79,95% CI 0.51-1.23) 2. An Israeli study of 1,329 first-trimester exposures similarly found no association with major malformations (adjusted OR 0.85,95% CI 0.67-1.08) 3.
Throughout pregnancy: A retrospective analysis of 91 pregnancies treated with nitrofurantoin showed no drug-related abnormal events, with outcomes comparable to the general U.S. population 4.
Critical Contraindication
Nitrofurantoin is absolutely contraindicated at term (38-42 weeks gestation), during labor and delivery, and in neonates under 1 month of age 1. This is due to the risk of hemolytic anemia in newborns with immature enzyme systems. One study found increased neonatal jaundice when nitrofurantoin was dispensed in the last 30 days before delivery (10.8% vs 8.1%, OR 1.31) 2.
Dosing Regimen
Treatment of Asymptomatic Bacteriuria or UTI in Pregnancy
100 mg orally twice daily for 7 days, taken with food 1.
This recommendation is strongly supported by:
The IDSA 2019 guideline specifically notes that a 7-day course is more effective than single-dose therapy for preventing adverse outcomes including lower birth weight 5. A randomized controlled trial of 778 pregnant women showed bacteriologic cure rates of 86.2% with 7-day treatment versus only 75.7% with 1-day treatment (difference -10.5%, 95% CI -16.1% to -4.9%) 6.
The 7-day regimen also resulted in significantly better birth outcomes, with higher mean birth weight and gestational age at delivery compared to the 1-day regimen 6.
Single-dose or shorter courses are inadequate for pregnancy. While nitrofurantoin and β-lactams are preferred for safety, they are less effective as short-course therapy compared to their use in non-pregnant women 5.
Prophylaxis for Recurrent UTI
For pregnant women with recurrent UTI history, postcoital prophylaxis with 50 mg nitrofurantoin as a single dose has proven highly effective, reducing UTI incidence from 130 infections over 7 months pre-pregnancy to only 1 infection during 39 pregnancies 7.
Clinical Considerations
Nitrofurantoin is preferred over fluoroquinolones and other broad-spectrum agents during pregnancy because it:
- Achieves high urinary concentrations with minimal systemic absorption
- Causes minimal collateral damage to gut and vaginal microbiota
- Has low resistance rates among uropathogens 8
Common pitfall: Do not use 3-day or 5-day courses in pregnancy as recommended for non-pregnant women. The evidence clearly supports 7 days for pregnant patients 5, 6.
Administration: Must be taken with food to optimize absorption 1.